Search results for "Anticoagulation"
MKSAP quiz on atrial fibrillation
This month's quiz includes questions from ACP's Medical Knowledge Self-Assessment Program (MKSAP 18) on atrial fibrillation.
https://acphospitalist.acponline.org/archives/2019/08/mksap-quiz-on-atrial-fibrillation.htm
15 Aug 2019
Duty hours, infective endocarditis
Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2019/08/recent-research.htm
15 Aug 2019
Major bleeding, mortality risks after VTE similar on DOACs or warfarin
The authors noted that the safety of DOAC treatment of VTE beyond 180 days remains uncertain and that 95% of DOAC users in the study were taking rivaroxaban, so further study of other agents is needed.
https://acphospitalist.acponline.org/weekly/archives/2017/10/25/3.htm
25 Oct 2017
Pulmonary embolism
For optimal documentation, coding, and reimbursement, the location or type of pulmonary embolism needs to be clearly identified.
https://acphospitalist.acponline.org/archives/2022/02/23/coding-corner-pulmonary-embolism.htm
23 Feb 2022
Therapeutic hypothermia, HAI network, and more
Summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2020/05/recent-research.htm
15 May 2020
New data on tocilizumab, convalescent plasma, anticoagulation for COVID-19
Recent studies found that tocilizumab was potentially harmful for ICU patients, indicated that convalescent plasma works better with higher antibody titers delivered earlier, and offered conflicting findings on anticoagulation. Other research compared mortality from COVID-19 over time.
https://acphospitalist.acponline.org/weekly/archives/2021/01/27/1.htm
27 Jan 2021
Dabigatran reversal agent worked for uncontrolled bleeding, urgent procedures
Patients with gastrointestinal bleeds, intracranial hemorrhages, or urgent need for surgery were given 5 g of intravenous idarucizumab to reverse the anticoagulant effect of dabigatran in the industry-funded study.
https://acphospitalist.acponline.org/weekly/archives/2017/07/19/4.htm
19 Jul 2017
Reports and recommendations on clot concerns with adenovirus COVID-19 vaccines
Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23.
https://acphospitalist.acponline.org/weekly/archives/2021/04/21/1.htm
21 Apr 2021
Latest research, recommendations cover diabetes, clots, and remdesivir in COVID-19
Mortality was lower in diabetes patients given sitagliptin at admission for COVID-19, ACP practice points support remdesivir, acquired thrombophilia does not predict clots, cardiac arrest survival is low, and admissions for other conditions were still way down over the summer.
https://acphospitalist.acponline.org/weekly/archives/2020/10/07/1.htm
7 Oct 2020
Rivaroxaban after discharge may reduce thromboembolic risk in medically ill
An industry-funded trial that gave medical patients rivaroxaban for 45 days after hospital discharge found decreased risk for a composite end point of symptomatic venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death compared to placebo.
https://acphospitalist.acponline.org/weekly/archives/2020/06/24/3.htm
24 Jun 2020